CO6230982A2 - Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen - Google Patents
Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienenInfo
- Publication number
- CO6230982A2 CO6230982A2 CO10102942A CO10102942A CO6230982A2 CO 6230982 A2 CO6230982 A2 CO 6230982A2 CO 10102942 A CO10102942 A CO 10102942A CO 10102942 A CO10102942 A CO 10102942A CO 6230982 A2 CO6230982 A2 CO 6230982A2
- Authority
- CO
- Colombia
- Prior art keywords
- optionally substituted
- nitrogen
- hydrocarbon group
- compound
- ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical class 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 abstract 1
- QACVMDXTCPLKOG-UHFFFAOYSA-N 2,4,7-trichloro-9-(4-methylphenyl)-7,8-dihydro-6h-purino[7,8-a]pyrimidine Chemical compound C1=CC(C)=CC=C1N1C2=NC3=NC(Cl)=NC(Cl)=C3N2CC(Cl)C1 QACVMDXTCPLKOG-UHFFFAOYSA-N 0.000 abstract 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporciona un compuesto de la fórmula (I'): en donde X es un nitrógeno o CRx, Rx es un hidrógeno, etc., R1 es un grupo de hidrocarburo opcionalmente substituido etc., R2 es un grupo de hidrocarburo opcionalmente substituido, etc., el anillo A es un anillo heterocíclico de 5- a -8-miembros etc., y cada uno de Y1, Y2 e Y3 es un carbono opcionalmente substituido o un nitrógeno, etc.; o una sal del mismo o un profármaco del mismo, que tiene actividad antagonista del receptor CRF y proporciona también el uso del mismo. 1.- Un compuesto representado por la fórmula (I'):en donde X es un nitrógeno o CRx (en donde Rx es un hidrógeno o un C1-9 alquilo, siempre y cuando X forme un enlace doble, Rx está ausente); R1 es (1) un grupo de hidrocarburo opcionalmente substituido, (2) un acilo, (3) un grupo heterocíclico opcionalmente substituido, (4) un amino opcionalmente substituido, (5) nitro, (6) un hidroxi opcionalmente substituido, (7) un mercapto opcionalmente substituido, (8) ciano, o (9) halógeno; R2 es (1) un grupo de hidrocarburo opcionalmente substituido, (2) un acilo, (3) un grupo heterocíclico opcionalmente substituido, o (4) un amino opcionalmente substituido, siempre y cuando se excluyan metilo, etilo, propilo y metoximetilo; el anillo A es un anillo heterocíclico de 5- a 8- miembros opcionalmente substituido; y Y1, Y2 e Y3 cada uno son un carbono o un nitrógeno opcionalmente substituido; excluyendo (i) un compuesto en donde Y1 e Y3 cada uno son un nitrógeno, R1 es amino y R2 es alquilo opcionalmente substituido, (ii) 2,4,7-tricloro-9-(4-metilfenil)-6,7,8,9-tetrahidropirimido [2,1-f] purina, (iii) N-acetil-N-(8-acetil-7,8-dihidro-6H-imidazo[2,1-f]purin-4-il)acetamida, y (iv) un compuesto en donde R1 y R2 cada uno son simultáneamente o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US655408P | 2008-01-22 | 2008-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6230982A2 true CO6230982A2 (es) | 2010-12-20 |
Family
ID=40637104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10102942A CO6230982A2 (es) | 2008-01-22 | 2010-08-20 | Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8901141B2 (es) |
| EP (1) | EP2240485B1 (es) |
| JP (1) | JP5431341B2 (es) |
| KR (1) | KR20100130596A (es) |
| CN (1) | CN101981031A (es) |
| AR (1) | AR070218A1 (es) |
| AU (1) | AU2009206936A1 (es) |
| BR (1) | BRPI0907230A2 (es) |
| CA (1) | CA2712347A1 (es) |
| CL (1) | CL2009000116A1 (es) |
| CO (1) | CO6230982A2 (es) |
| CR (1) | CR11636A (es) |
| DO (1) | DOP2010000226A (es) |
| EA (1) | EA201070876A1 (es) |
| EC (1) | ECSP10010414A (es) |
| GE (1) | GEP20125637B (es) |
| IL (1) | IL207074A0 (es) |
| MA (1) | MA32438B1 (es) |
| MX (1) | MX2010008039A (es) |
| NZ (1) | NZ587215A (es) |
| PE (1) | PE20091439A1 (es) |
| SG (1) | SG189803A1 (es) |
| TW (1) | TW200936591A (es) |
| UY (1) | UY31604A1 (es) |
| WO (1) | WO2009093747A1 (es) |
| ZA (1) | ZA201005340B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| CA2752073A1 (en) * | 2009-02-11 | 2010-08-19 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| US20120172350A1 (en) * | 2009-09-11 | 2012-07-05 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| MY166866A (en) | 2011-08-18 | 2018-07-24 | Nippon Shinyaku Co Ltd | Heterocyclic derivative and pharmaceutical drug |
| EP2825541B1 (en) | 2012-03-16 | 2016-06-22 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
| BR112014022780A8 (pt) | 2012-03-16 | 2021-06-15 | Vitae Pharmaceuticals Inc | composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| CN103435618B (zh) * | 2013-08-22 | 2016-03-23 | 中国药科大学 | 一种合成稠杂环化合物的方法 |
| AU2015261775B2 (en) | 2014-05-23 | 2019-07-11 | Active Biotech Ab | Novel compounds useful as S100-inhibitors |
| CN105859630B (zh) * | 2015-01-22 | 2019-01-18 | 北京大学 | 一种咪唑酮衍生物的合成方法及应用 |
| WO2017056055A1 (en) | 2015-10-01 | 2017-04-06 | Idemitsu Kosan Co., Ltd. | Benzimidazolo[1,2-a]benzimidazole carrying triazine groups for organic light emitting diodes |
| EP3150604B1 (en) | 2015-10-01 | 2021-07-14 | Idemitsu Kosan Co., Ltd. | Benzimidazolo[1,2-a]benzimidazole carrying benzimidazolo[1,2-a]benzimidazolylyl groups, carbazolyl groups, benzofurane groups or benzothiophene groups for organic light emitting diodes |
| WO2018220513A1 (en) * | 2017-05-31 | 2018-12-06 | Alembic Pharmaceuticals Limited | An improved process for preparation of obeticholic acid |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS516993A (en) | 1974-07-05 | 1976-01-20 | Dainippon Pharmaceutical Co | Adeninjudotaino seiho |
| PT1354884E (pt) | 2000-12-28 | 2007-12-24 | Ono Pharmaceutical Co | Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
| CA2562244A1 (en) * | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| TWI370820B (en) * | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| US20100056515A1 (en) | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
| EP2125753A1 (en) | 2006-12-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds having crf antagonistic activity |
| DK2252581T3 (da) | 2008-01-22 | 2012-07-16 | Lilly Co Eli | Kappa-selektiv opioidreceptorantagonist |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| FR2926554B1 (fr) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| AR070220A1 (es) | 2008-01-22 | 2010-03-25 | Boehringer Ingelheim Int | Amino-bencimidazoles sustituidos medicamentos que comprenden dicho compuestos, uso y metodos de fabricacion de los mismos |
-
2009
- 2009-01-21 JP JP2010528624A patent/JP5431341B2/ja not_active Expired - Fee Related
- 2009-01-21 TW TW098102200A patent/TW200936591A/zh unknown
- 2009-01-21 CL CL2009000116A patent/CL2009000116A1/es unknown
- 2009-01-21 AR ARP090100180A patent/AR070218A1/es not_active Application Discontinuation
- 2009-01-21 US US12/863,851 patent/US8901141B2/en not_active Expired - Fee Related
- 2009-01-21 EA EA201070876A patent/EA201070876A1/ru unknown
- 2009-01-21 KR KR1020107018307A patent/KR20100130596A/ko not_active Application Discontinuation
- 2009-01-21 GE GEAP200911925A patent/GEP20125637B/en unknown
- 2009-01-21 WO PCT/JP2009/051299 patent/WO2009093747A1/en active Application Filing
- 2009-01-21 CN CN2009801105455A patent/CN101981031A/zh active Pending
- 2009-01-21 US US12/357,158 patent/US8785460B2/en not_active Expired - Fee Related
- 2009-01-21 MX MX2010008039A patent/MX2010008039A/es not_active Application Discontinuation
- 2009-01-21 PE PE2009000069A patent/PE20091439A1/es not_active Application Discontinuation
- 2009-01-21 AU AU2009206936A patent/AU2009206936A1/en not_active Abandoned
- 2009-01-21 CA CA2712347A patent/CA2712347A1/en not_active Abandoned
- 2009-01-21 BR BRPI0907230A patent/BRPI0907230A2/pt not_active IP Right Cessation
- 2009-01-21 EP EP09704168.5A patent/EP2240485B1/en active Active
- 2009-01-21 SG SG2013029723A patent/SG189803A1/en unknown
- 2009-01-21 UY UY031604A patent/UY31604A1/es not_active Application Discontinuation
- 2009-01-21 NZ NZ587215A patent/NZ587215A/xx not_active IP Right Cessation
-
2010
- 2010-07-18 IL IL207074A patent/IL207074A0/en unknown
- 2010-07-21 DO DO2010000226A patent/DOP2010000226A/es unknown
- 2010-07-27 ZA ZA2010/05340A patent/ZA201005340B/en unknown
- 2010-08-13 MA MA33084A patent/MA32438B1/fr unknown
- 2010-08-18 CR CR11636A patent/CR11636A/es not_active Application Discontinuation
- 2010-08-20 EC EC2010010414A patent/ECSP10010414A/es unknown
- 2010-08-20 CO CO10102942A patent/CO6230982A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201005340B (en) | 2011-10-26 |
| TW200936591A (en) | 2009-09-01 |
| CN101981031A (zh) | 2011-02-23 |
| WO2009093747A1 (en) | 2009-07-30 |
| US20090186879A1 (en) | 2009-07-23 |
| ECSP10010414A (es) | 2010-09-30 |
| MA32438B1 (fr) | 2011-07-03 |
| CL2009000116A1 (es) | 2010-08-27 |
| EP2240485A1 (en) | 2010-10-20 |
| CA2712347A1 (en) | 2009-07-30 |
| SG189803A1 (en) | 2013-05-31 |
| AU2009206936A1 (en) | 2009-07-30 |
| EP2240485B1 (en) | 2014-10-15 |
| KR20100130596A (ko) | 2010-12-13 |
| NZ587215A (en) | 2012-08-31 |
| BRPI0907230A2 (pt) | 2019-09-24 |
| IL207074A0 (en) | 2010-12-30 |
| GEP20125637B (en) | 2012-09-10 |
| EA201070876A1 (ru) | 2011-04-29 |
| UY31604A1 (es) | 2009-08-31 |
| MX2010008039A (es) | 2010-08-10 |
| JP2011509923A (ja) | 2011-03-31 |
| AR070218A1 (es) | 2010-03-25 |
| PE20091439A1 (es) | 2009-10-19 |
| DOP2010000226A (es) | 2010-10-15 |
| JP5431341B2 (ja) | 2014-03-05 |
| CR11636A (es) | 2010-11-04 |
| US8785460B2 (en) | 2014-07-22 |
| US20100298287A1 (en) | 2010-11-25 |
| US8901141B2 (en) | 2014-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6230982A2 (es) | Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR064197A1 (es) | Derivados de pirimidina y piridina inhibidores de la proteina quinasa | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| PE20121312A1 (es) | Metodo para preparar compuestos macrociclicos inhibidores de serina proteasas de hepatitis c | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| HN2010001059A (es) | Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes. | |
| UY32296A (es) | Nuevos compuestos | |
| PE20151413A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| PE20120172A1 (es) | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide | |
| RS51919B (en) | BENZOTIAZEPINE DERIVATIVES AND THEIR USE AS AMP AND NMDA RECEPTOR MODULATORS | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| CO6260077A2 (es) | Pirimidinas biciclicas fusionadas | |
| ECSP099394A (es) | Derivados de quinuclidinol como antogonistas de receptores muscarínicos | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| MX2010001190A (es) | Compuesto biciclico fusionado. | |
| CO6801736A2 (es) | Derivados heterocíclicos de amina | |
| UY29798A1 (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| ECSP099565A (es) | Compuesto de 2-amino pirimidina | |
| NI201000011A (es) | Derivados de pirimidina 934. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |